Close Menu

More articles about Biomarker Discovery & Validation

The funding marks the second cycle of CZI's Essential Open Source Software program, which awards between $50,000 and $250,000 in total costs per project.

Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.

The partners aim to develop unbiased omics-based methods for identifying cases of PTSD, which may increase in the wake of the COVID-19 pandemic.

Erisyon will use its single-molecule protein sequencing technology to detect and validate biomarkers for early detection of Parkinson's disease.

Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.

Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.

Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.

The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.

The study, which is being supported by Thermo Fisher Scientific, aims to identify genetic biomarkers that can predict patients likely to develop severe disease.

The alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.

The HRM-based method developed by Chinese researchers could also serve as an alternative genetic test when other methods are unavailable or too expensive. 

The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.   

Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.

The team believes that the project will find genetic factors involved in the development of severe COVID-19 in patients that lack risk factors. 

High throughput and deep coverage have allowed firms like Olink and Somalogic to make inroads, especially among researchers working outside proteomics.

The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.

The technology uses photostable and bright phosphor-integrated dots for quantitative, amplification-free detection of proteins at cellular and subcellular levels.

The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.

The partners will use Medidata's machine learning-based biomarker discovery platform to investigate the amyotrophic lateral sclerosis disease process.

The firm said current adoption is robust, but enabling readout on NGS instruments this summer will be crucial to opening a much larger customer base.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.